Evidence map›Paper›PMID 34424444›Full record

ReviewMolecular biology reports2021

Nanotechnology-based immunotherapies to combat cancer metastasis.

Yuping Zhao, Muhammad Bilal, Maimoona Qindeel, Muhammad Imran Khan, Kuldeep Dhama, Hafiz M N Iqbal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuping ZhaoSchool of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian, 223003, China. zhaoyuping@hyit.edu.cn.
Muhammad BilalSchool of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian, 223003, China.ORCID http://orcid.org/0000-0001-5388-3183
Maimoona QindeelDepartment of Pharmacy, Quaid-i-Azam University, Islamabad, 45320, Pakistan.
Muhammad Imran KhanHefei National Lab for Physical Sciences at the Microscale and the Centers for Biomedical Engineering, University of Science and Technology of China, Hefei, 230027, Anhui, China.ORCID http://orcid.org/0000-0001-6898-4630
Kuldeep DhamaDivision of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, 243 122, India.
Hafiz M N IqbalTecnologico de Monterrey, School of Engineering and Sciences, 64849, Monterrey, Mexico. hafiz.iqbal@tec.mx.ORCID http://orcid.org/0000-0003-4855-2720

Funding

Sistema Nacional de Investigadores CVU: 735340
6 · The paper itself

Abstract

Emerging concepts in nanotechnology have gained particular attention for their clinical translation of immunotherapies of cancer, autoimmune and infectious diseases. Several nanoconstructs have been engineered with unique structural, physicochemical, and functional features as robust alternatives for conventional chemotherapies. Traditional cancer therapies like chemotherapy, radiotherapy, and ultimately surgery are the most widely practiced in biomedical settings. Biomaterials and nanotechnology have introduced vehicles for drug delivery and have revolutionized the concept of the modern immunotherapeutic paradigm. Various types of nanomaterials, such as nanoparticles and, more specifically, drug-loaded nanoparticles are becoming famous for drug delivery applications because of safety, patient compliance, and smart action. Such therapeutic modalities have acknowledged regulatory endorsement and are being used in twenty-first-century clinical settings. Considering the emerging concepts and landscaping potentialities, herein, we spotlight and discuss nanoparticle-based immunotherapies as a smart and sophisticated drug delivery approach to combat cancer metastasis. The introductory part of this manuscript discusses a broad overview of cancer immunotherapy to understand better the tumor microenvironment and nanotechnology-oriented immunomodulatory strategies to cope with advanced-stage cancers. Following that, most addressable problems allied with conventional immunotherapies are given in comparison to nanoparticle-based immunotherapies. The later half of this work comprehensively highlights the requisite delivery of various bioactive entities with particular cases and examples. Finally, this review also encompasses a comprehensive concluding overview and future standpoints to strengthen a successful clinical translation of nanoparticle-based immunotherapies as a smart and sophisticated drug delivery approach.

Indexed as

AnimalsAntineoplastic AgentsHumansImmunomodulating AgentsImmunotherapyNanoparticle Drug Delivery SystemNanoparticlesNanotechnologyNeoplasm MetastasisNeoplasmsTreatment OutcomeTumor MicroenvironmentAntineoplastic AgentsImmunomodulating AgentsNanoparticle Drug Delivery SystemBiomedicalCancer battleDrug deliveryImmunotherapeuticNanoparticlesTumor metastasis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.